mantle cell lymphoma

News

Brukinsa data raises chemo-free hope for mantle cell lymphom...

Patients with newly diagnosed mantle cell lymphoma could avoid chemotherapy with a regimen based on BeOne's Brukinsa, according to the MANGROVE trial.

News

FDA hands BeOne, Taiho approvals for blood cancers

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

FDA starts priority review of BeOne's Venclexta rival

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

NICE backs new drugs for Crohn's disease, lymphoma

Eli Lilly's Omvoh has been recommended for use in Crohn's disease by NICE, while BeOne's Brukinsa gets the go-ahead for mantle cell lymphoma.

News

Microscope view of nodular mantle cell lymphoma

AZ's Calquence gets first-line OK in mantle cell lymphoma

AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.

News

AZ’s Calquence extends disease-free survival in MCL

AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival

Brukinsa data raises chemo-free hope for mantle cell lymphom...

FDA hands BeOne, Taiho approvals for blood cancers

FDA starts priority review of BeOne's Venclexta rival

NICE backs new drugs for Crohn's disease, lymphoma

AZ's Calquence gets first-line OK in mantle cell lymphoma

AZ’s Calquence extends disease-free survival in MCL

Lundbeck preps for key bexicaserin data around year-end

Discover a new era of healthcare panel engagement: Grounded ...

mantle cell lymphoma

Editor's Picks